N-乙基-4-氯苄胺 | 69957-83-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-4-氯苄胺
• 中文别名: 4-氯-N-乙基苄胺
• 英文名称: N-(4-chlorobenzyl)ethanamine
• 英文别名: N-Ethyl-4-chlorobenzylamine；N-[(4-chlorophenyl)methyl]ethanamine
• CAS: 69957-83-1
• 化学式: C₉H₁₂ClN
• mdl: MFCD00045212
• 分子量: 169.654
• InChiKey: DWQGKMSNZGJKJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险品运输编号：
  2735
• 危险性描述：
  H314

反应信息

• 作为反应物：
  描述：

  N-乙基-4-氯苄胺 在 盐酸 、 铁粉 、 三乙胺 作用下， 以 乙二醇乙醚 为溶剂， 反应 2.0h， 生成 3-amino-6-[(4-chlorophenyl)methyl-ethylamino]pyridine-2-carbonitrile
  参考文献：
  名称：

  叶酸拮抗剂。21.2，4-二氨基-6-（苄基氨基）吡啶并[3，2-d]嘧啶的合成和抗疟性质。

  摘要：

  描述了一系列2,4,6-三氨基吡啶并[3,2-d]嘧啶（4）的合成及抗疟活性。与相应的喹唑啉类似物相比，几种6-取代的苄基甲基氨基类似物对小鼠中滋养体诱导的伯氏疟原虫的活性更高。但是，这些试剂对其他抗叶酸化合物具有交叉耐药性，因此作为人用试剂的潜力有限。

  DOI：

  10.1021/jm00380a018
• 作为产物：
  描述：

  [1-(4-Chloro-phenyl)-meth-(E)-ylidene]-ethyl-amine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 N-乙基-4-氯苄胺
  参考文献：
  名称：

  Novel Pyrrolidine Ureas as C−C Chemokine Receptor 1 (CCR1) Antagonists

  摘要：

  Monocyte infiltration is implicated in a variety of diseases including multiple myeloma, rheumatoid arthritis, and multiple sclerosis. C-C chemokine receptor 1 (CCR1) is a chemokine receptor that upon stimulation, particularly by macrophage inflammatory protein 1 alpha (MIP-1 alpha) and regulated on normal T-cell expressed and secreted (RANTES), mediates monocyte trafficking to sites of inflammation. High throughput screening of our combinatorial collection identified a novel, moderately potent CCR1 antagonist 3. The library hit 3 was optimized to the advanced lead compound 4. Compound 4 inhibited CCR1 mediated chemotaxis of monocytes with an IC50 of 20 nM. In addition, the compound was highly selective over other chemokine receptors. It had good microsomal stability when incubated with rat and human liver microsomes and showed no significant cytochrome P450 (CYP) inhibition. Pharmacokinetic evaluation of the compound in the rat showed good oral bioavailability.

  DOI：

  10.1021/jm801416q

文献信息

• [EN] AZETIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'AZÉTIDINE UTILES POUR LE TRAITEMENT DE MALADIES MÉTABOLIQUES ET INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2012098033A1

  公开（公告）日：2012-07-26

  Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

  披露了具有以下表示的公式的化合物：这些化合物可以制备为药物组合物，并可用于预防和治疗包括人类在内的哺乳动物的各种疾病，例如炎症性疾病、传染病、自身免疫疾病、涉及免疫细胞功能受损的疾病、心脏代谢疾病和/或增殖性疾病，举例不限。
• Isoquinolinamine and phthalazinamine derivatives: corticotropin-releasing factor receptor CRF1 specific ligands
  申请人：Neurogen Corporation

  公开号：US06353103B1

  公开（公告）日：2002-03-05

  Disclosed are compounds that are highly selective partial agonists or antagonists at human CRF1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety. The compounds have the formula or the pharmaceutically acceptable salts thereof wherein Ar, R1, R2, R3, R4 and W are various organic and inorganic substituents.

  本文披露了一种在人类CRF1受体上高度选择性的部分激动剂或拮抗剂，可用于诊断和治疗与压力相关的疾病，如创伤后应激障碍（PTSD），以及抑郁症、头痛和焦虑症。这些化合物具有以下结构式： 或其药用可接受的盐，其中Ar、R1、R2、R3、R4和W为各种有机和无机取代基。
• <i>gem</i> ‐Difluoroallylation of Aryl Halides and Pseudo Halides with Difluoroallylboron Reagents in High Regioselectivity
  作者：Shu Sakamoto、Trevor W. Butcher、Jonathan L. Yang、John F. Hartwig

  DOI：10.1002/anie.202111476

  日期：2021.12

  coupling of a difluoroallylboronate with aryl and heteroaryl halides and triflates provides a convenient and broadly applicable synthesis of difluoroallylarenes. The difluoroallyl boron reagent is formed by a copper-catalyzed defluorinative borylation of the inexpensive reagent 3,3,3-trifluoropropene, and the products undergo a wide range of reactions to a series of difluoro-substituted analogs of common

  二氟烯丙基硼酸酯与芳基和杂芳基卤化物和三氟甲磺酸酯的偶联提供了方便且广泛适用的二氟烯丙基芳烃的合成。二氟烯丙基硼试剂是通过铜催化的廉价试剂 3,3,3-三氟丙烯的脱氟硼基化形成的，并且产物经历广泛的反应，形成一系列常见的具有生物价值的结构单元的二氟取代的类似物。
• [EN] ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE<br/>[FR] DERIVES DE L'ACIDE BENZOIQUE ORTHO-SUBSTITUES DESTINES AU TRAITEMENT DE L'INSULINORESISTANCE
  申请人：ASTRAZENECA AB

  公开号：WO2004000294A1

  公开（公告）日：2003-12-31

  The present invention provides a compound of formula (I), wherein n is 0, 1 or 2; R1 represents halo, a C1-4alkyl group which is optionally substituted by one or more fluoro, a C1-4alkoxy group which is optionally substituted by one or more fluoro and wherein when n is 2 the substituents R1 may be the same or different; R2 represents an unbranched C2-7alkyl group; R3 represents H or OCH3; and W represents O or S and pharmaceutically acceptable salts and prodrugs thereof, to processes for preparing such compounds, to their utility in treating clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  本发明提供了一种式(I)化合物，其中n为0、1或2；R1代表卤素、可被一个或多个氟取代的C1-4烷基、可被一个或多个氟取代的C1-4烷氧基，且当n为2时，取代基R1可以相同或不同；R2代表直链C2-7烷基；R3代表H或OCH3；W代表O或S及其药学上可接受的盐和前药，以及制备此类化合物的方法，它们在治疗与胰岛素抵抗相关的临床条件中的用途，其治疗方法以及含有它们的药物组合物。
• Therapeutic agents
  申请人：Alstermark Lindstedt Eva-Lotte

  公开号：US20050282822A1

  公开（公告）日：2005-12-22

  The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them.

  本发明提供了一种I式化合物，以及制备这种化合物的方法，它们在治疗临床病症中的应用，包括与胰岛素抵抗有关的脂质紊乱（脂质代谢异常），以及它们的治疗用途和含有它们的药物组合物。